Important Safety Information
|
 |
| |
For patients 65 years of age and older— |
|
|
|
|
 |
|
|
 |
 |
|
| HELP PROTECT |
| YOUR SENIOR |
| PATIENTS |
| WITH FLUZONE HIGH-DOSE |
| VACCINE—DESIGNED |
| SPECIFICALLY FOR THEM1 |
|
|
|
 |
|
 |
 |
IN A RANDOMIZED, MULTICENTER, DOUBLE-BLIND TRIAL
of Fluzone High-Dose vaccine and Fluzone vaccine, with 31,803 adults
65 years of age and older, Fluzone High-Dose vaccine was proven to1,2,a: |
|
|
 |
| — PROVIDE SUPERIOR EFFICACY compared to Fluzone vaccine |
|
|
|
|
RESERVE FLUZONE HIGH-DOSE VACCINE TODAY for the 2015-2016 influenza season |
|
|
| |
|
a Per-protocol analysis set for efficacy assessments.1 |
|
| |
| |
| IMPORTANT SAFETY INFORMATION |
| |
| INDICATION |
| |
| Fluzone High-Dose vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine. |
| |
| Fluzone High-Dose vaccine is approved for use in persons 65 years of age and older. |
| |
| SAFETY INFORMATION |
| |
| The most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever. Other adverse reactions may occur. Fluzone High-Dose vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine. |
| |
| If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone High-Dose vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone High-Dose vaccine may not protect all individuals. |
| |
Before administering Fluzone High-Dose vaccine, please see accompanying full
Prescribing Information. |
| |
|
| Fluzone High-Dose and Fluzone vaccines are manufactured and distributed by Sanofi Pasteur Inc. |
|
| Fluzone High-Dose vaccine (CPT ®b code 90662) is a covered benefit under Medicare Part B. |
|
 |
|
|
| |
| b CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association. |
|
| |
References: 1. Fluzone High-Dose vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2014. 2.DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-645. 3. Centers for Disease Control and Prevention (CDC). Seasonal influenza (flu): estimating seasonal influenza-associated deaths in the United States: CDC study confirms variability of flu. http://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm. Accessed April 15, 2015. 4. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009;27:5043-5053. 5. CDC. Flu vaccination coverage: United States, 2012-13 influenza season. http://www.cdc.gov/flu/pdf/fluvaxview/vax-coverage-1213estimates.pdf. Accessed April 15, 2015. |
| |
|
|
|
| |
 |
|
|
|
|
|
eniors, it's that time of year.
